nicht kleckern ..klotzen ::POZEN

Date Requested 09/09/13
Last Trade $5.76
Split Adjustment Factor 1.0000:1  
Day's Low $5.56
Day's High $5.77
Open $5.71
Volume 163,542

Exchange- NASDAQ NM


NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Actual Price is not adjusted for splits or dividends. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown above.

The closing price above is not necessarily indicative of future price performance.
http://investors.pozen.com/...tml?c=121701&p=irol-historicalPrice  

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
_______________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

09/04/13 8-K Report of unscheduled material events or corporate event Current Reports        
http://investors.pozen.com/phoenix.zhtml?c=121701&p=irol-sec

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 4, 2013

POZEN INC.

(Exact Name of Registrant as Specified in Charter)

  Delaware 000-3171962-1657552§
(State or Other Jurisdiction
of Incorporation) (Commission
File Number) (IRS Employer
Identification No.)



1414 Raleigh Road, Suite 400
Chapel Hill, North Carolina
27517
(Address of Principal Executive Offices) (Zip Code)


(919) 913-1030
(Registrant's telephone number, including area code)


Not applicable
(Former Name or Former Address, if Changed Since Last Report)

  §Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

  §Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

  §Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

  §Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).



















Item 1.01 Entry into a Material Definitive Agreement

On September 3, 2013, POZEN Inc. (“POZEN”) entered into a License and Collaboration Agreement (the “ License Agreement ”) with sanofi-aventis U.S. LLC (“ Sanofi ”).  Under the License Agreement, POZEN will have the responsibility for obtaining regulatory approval and Sanofi will have responsibility for the commercialization of products containing a combination of immediate release omeprazole and 325 mg or less of delayed release aspirin, including PA32540 and PA8140, which are expected to be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.

Under the License Agreement, Sanofi has the exclusive right to commercialize licensed products in the United States, with POZEN retaining the right to commercialize licensed products outside the United States.  Sanofi will have responsibility for all sales, marketing and future development for the licensed products.  In addition, following approval of the New Drug Application (NDA) and completion of certain manufacturing milestones, Sanofi will have responsibility for manufacturing the licensed products for commercialization in the United States.  POZEN will retain responsibility for obtaining approval of the NDA, filed with the U.S. Food and Drug Administration (FDA) in March 2013, after which time POZEN will transfer the NDA to Sanofi.  The parties will share costs up to certain limits with respect to certain additional development activities required in order to obtain or maintain regulatory approval in the United States.   During the term of the License Agreement, POZEN may not commercialize in the United States, or license any third party to commercialize in the United States, any product combining any product indicated for treatment of gastric ulcers or gastric bleeding, or both, and 325 mg or less of aspirin.

In consideration for the rights granted to Sanofi under the License Agreement, Sanofi will pay to POZEN an upfront payment of $15 million.  POZEN is also eligible to receive pre-commercial milestone payments of $20 million and additional payments upon the achievement of specified sales milestones.  POZEN will also receive double-digit tiered royalties on sales of licensed products by Sanofi, its affiliates and its sublicensees in the United States, subject to certain adjustments specified in the License Agreement.

Sanofi will use commercially reasonable efforts to commercialize the licensed products and has agreed to specified advertising and promotional expense levels and sales details for the first two years after launch.  In the event net sales for licensed products are less than a specified amount during the third full year of commercialization, POZEN may notify Sanofi that it wishes to purchase back from Sanofi all rights to the licensed products in the United States.    In the event POZEN wishes to exercise its option, Sanofi will have the first right to buy out POZEN’s remaining interest.

The License Agreement will terminate upon the expiration of Sanofi’s royalty payment obligations, which occurs, on a licensed product-by-licensed product basis, upon the latest of (i) expiration of the last-to-expire patent covering a licensed product and (ii) a specified number of years following first commercial sale of such licensed product.  Sanofi may terminate the License Agreement at will in its entirety any time after the third anniversary of the effective date of the License Agreement.  The License Agreement may also be terminated by either party if the other party fails to cure certain material breaches under the License Agreement.   In addition, Sanofi may terminate the License Agreement under certain other specified circumstances.

The foregoing is a summary description of certain terms of the License Agreement and does not purport to be complete, and it is qualified in its entirety by reference to the full text of the License Agreement, which POZEN intends to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2013, with confidential terms redacted..

A copy of the press release issued in connection with the parties’ announcement of the Agreement is attached hereto as 99.1 and incorporated herein by reference.



2










SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

POZEN Inc.

By: /s/ William L. Hodges
Name: William L. Hodges
Title: Chief Financial Officer


Date:  September 4, 2013
 

1414 RALEIGH ROAD

SUITE 400

CHAPEL HILL NC 27517 Business Address
1414 RALEIGH ROAD

SUITE 400

CHAPEL HILL NC 27517
919-913-1030POZEN INC /NC (Filer) CIK: 0001059790 (see all company filings)
IRS No.: 621657552 | Fiscal Year End: 0919
Type: 10-K | Act: 34 | File No.: 000-31719 | Film No.: 12681216
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1
http://www.sec.gov/cgi-bin/...er=0001140361-12-014567&xbrl_type=v  

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
  Expires:§December 31, 2014
Estimated average burden
hours per response 0.5


 
          §Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
PAR INVESTMENT PARTNERS LP





    (Last)   (First)  (Middle)§
ONE INTERNATIONAL PLACE SUITE 2401




(Street)
    BOSTON        MA02110




§
    (City)   (State)     (Zip)          §
          §2. Issuer Name and Ticker or Trading Symbol
POZEN INC /NC [POZN] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)


3. Date of Earliest Transaction (Month/Day/Year)
07/17/2013
4. If Amendment, Date of Original Filed (Month/Day/Year)
          §6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
         X§Form filed by More than One Reporting Person
          §

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1) 07/17/2013 P 90,000 A $ 5.25 3,356,299 D(1)


Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date
(Month/Day/Year) 7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
PAR INVESTMENT PARTNERS LP





    (Last)   (First)  (Middle)§
ONE INTERNATIONAL PLACE SUITE 2401




(Street)
    BOSTON        MA02110




§
    (City)   (State) (Zip)
§
1. Name and Address of Reporting Person*
PAR Group, L.P.





    (Last)   (First)  (Middle)§
ONE INTERNATIONAL PLACE SUITE 2401




(Street)
    BOSTON        MA02110




§
    (City)   (State) (Zip)
§
1. Name and Address of Reporting Person*
PAR CAPITAL MANAGEMENT INC





    (Last)   (First)  (Middle)§
ONE INTERNATIONAL PLACE SUITE 2401




(Street)
    BOSTON        MA02110




§
    (City)   (State) (Zip)
§
Explanation of Responses:
1. These securities are held directly by PAR Investment Partners, L.P. ("PIP"). PAR Group, L.P. ("PAR Group") is the general partner of PIP. PAR Group disclaims beneficial ownership of the securities except to the extent of the pecuniary interest, if any, in such securities as a result of PAR Group's general partner interest in PIP and contingent right to a performance-based advisory fee. PAR Capital Management, Inc. ("PCM") is the general partner of PAR Group which is the general partner of PIP. PCM disclaims beneficial ownership of the securities except to the extent of the pecuniary interest, if any, in such securities as a result of PCM's general partner interest in PAR Group.
PAR Investment Partners, L.P. by PAR Group, L.P. its General Partner, by PAR Capital Management, Inc. its General Partner /s/: Steven M. Smith, Chief Operating Officer and General Counsel 07/19/2013
PAR Group, L.P. by PAR Capital Management, Inc. its General Partner /s/: Steven M. Smith, Chief Operating Officer and General 07/19/2013
PAR Capital Management, Inc. /s/: Steven M. Smith, Chief Operating Officer and General Counsel 07/19/2013
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
07/19/13 4 Statement of changes in beneficial ownership of securities 3,4,5        
http://investors.pozen.com/...=irol-sec&control_selectgroup=3,4,5  

Analysts
Firm Name Analyst Name Phone
Ascendiant Capital Markets, LCC Keay  Nakae, CFA  (949) 259-4933
ROTH Capital Partners Robert Hazlett (646) 358-1912
Zacks Equity Research Jason Napodano (312) 265-9421



Estimates
First Call Mean Estimates
Fiscal Year Ending: Dec - Last Changed: 09/06/13
YR Ending Q1
Mar  Q2
Jun  Q3
Sep  Q4
Dec  FISC YR Annual NUM Brokers (FISC) CAL YR Annual NUM Brokers (CAL)
2017             1.57  1  1.57  1  
2016             0.80  1  0.80  1  
2015             0.34  1  0.34  1  
2014  -0.04 0.29  0.17  -0.15  0.41  2  0.41  2  
2013  -0.19A -0.13A -0.09  0.55  0.14  2  0.14  2  
2012  -0.28A -0.17A -0.19A -0.20A -0.84  5  -0.84  0  
2011  -0.19A -0.21A -0.24A 2.04A 1.40  3  1.40  0  
2010  -0.10A 0.53A -0.29A 0.61A 0.76  6  0.76  5  
2009  -0.12A -0.14A 0.22A -0.19A -0.23  6  -0.23  6  
2008  -0.25A 0.43A -0.26A -0.14A -0.20  5  -0.20  5  
2007  -0.07A -0.13A 0.48A -0.14A 0.15  10  0.15  10  
2006  -0.22A -0.29A -0.14A -0.01A -0.66  10  -0.66  10  
2005  -0.19A -0.14A -0.16A 0.54A 0.07  5    

Mean Recommendation: 1.67
Mean Future 5 Year Growth Rate: 30
http://investors.pozen.com/...zhtml?c=121701&p=irol-earningsTable  

::::::: 5,90 $ +0,68% +0,04 $ In Euro: 4,3758 € | Nasdaq ,GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
09.10.13 5,64 5,66 5,51  5,58 $ 159.557 0,84 M

GrB  

Frankfurt 4,205 € München 4,205 € Nasdaq 7,02 $ buran und MfG und tau
 

RTK 5,70  $ RTP +2,15 EK 5,58 $  last 100 full 67.013 peak 5,755 ,GrB  

Preis 5,70 $ Schleife 300 spread 0,18%  

:::::::::::::::::::::::: 4,572 € +3,67% +0,162 € ,GrB
 

Datum Erster Hoch Tief Schluss     Stücke Volumen
24.10.13 6,25 6,48 6,1998  6,44 $ 822.889 5,21 M

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  13.11.13      5,71      5,84§5,6401 5,81 $ 148.248 0,84 M

GrB
 

Datum Erster Hoch Tief Schluss     Stücke Volumen
19.11.13 6,27 7,00 6,05   6,68 $ 1.812.292 11,7 M

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.11.13 6,80 6,81 6,65   6,80 $ 580.288 3,66 M

GrB  

Zeit   Kurs Stück
10:29:31 6,017 € 500
08:03:19 5,943 € 1.500
__________________
GRATULATION  

RTK 7,8801  $ RTP -0,13 EK 7,89 $ last shares 193 full RT 97.150 peak 7,90 buran und MfG und danke und weitermachen  

Zeit    Kurs Stück
  19:52:36§6,224 € 144
_________________
GRATULATION          §
 

SK 8,76  $ SKP +5,54 EK 8,30 $ last shares 253 full 813.682 peak 8,86

buran und MfG und danke und sowieso und überhaupt und HOLLA DIE WALDFEE  

Zeit      Kurs Stück
  12:43:23§6,488 € 70
________________
GRATULATION  

RTK 8,89  $ RTP +1,48 EK 8,76 $ last shares 190 full realtime 47.574 peak 8,89

buran und MfG und danke und weiter immer weiter immer schneller wie PROPELLER  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  11.12.13     6,241     6,488§6,241 6,488 € 70 454

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  11.12.13      8,77      9,12§8,455 8,74 $ 778.196 6,66 M

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  03.01.14      8,30      8,32§7,95 8,14 $ 430.725 3,42 M

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  10.01.14     5,899     6,141§5,899 6,141 € 1.400 8.596

GrB